Quantum BioPharma Ltd. (NASDAQ: QNTM) is advancing its lead drug candidate, Lucid-MS, toward a randomized, double-blind, placebo-controlled phase 2 clinical trial in multiple sclerosis (MS) after the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application. The announcement marks a significant step for the company's wholly owned subsidiary, Lucid Psycheceuticals Inc., which focuses on the research and development of Lucid-MS.
Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2). Unlike many existing MS therapies that suppress the immune system, Lucid-MS is designed to target demyelination directly, the underlying mechanism of multiple sclerosis. Preclinical models have shown that Lucid-MS can prevent and reverse myelin degradation, suggesting a novel approach to treating the disease.
The FDA's clearance of the IND application allows Quantum BioPharma to proceed with planning the phase 2 trial. This milestone is critical because it enables the company to test Lucid-MS in human patients and gather essential data on safety and efficacy. If successful, Lucid-MS could offer a new treatment option for MS patients who currently rely on immune-modulating therapies that may not address the root cause of demyelination.
In addition to the clinical progress, Quantum BioPharma is engaged in a research collaboration with Massachusetts General Hospital and Harvard Medical School involving the [¹⁸F]3F4AP PET imaging tracer. This tracer is being evaluated as a method to visualize and measure demyelination, which could provide valuable insights into disease progression and treatment response. Such imaging tools may enhance the development of therapies like Lucid-MS by allowing researchers to directly observe myelin repair in the brain.
The broader biopharmaceutical landscape includes several companies advancing therapies in areas of unmet medical need. For instance, Novartis AG (NYSE: NVS) recently received FDA approval for Pluvicto® in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA™ accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a phase 2 trial of BRIUMVI® in adults with treatment-resistant schizophrenia, and Bristol-Myers Squibb Company (NYSE: BMY) reported positive phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma.
These developments highlight the industry's ongoing efforts to address challenging diseases, but Quantum BioPharma's focus on MS is particularly notable given the limited options for directly targeting demyelination. The company's pipeline also includes UNBUZZD™, an over-the-counter product spun out to Unbuzzd Wellness Inc., in which Quantum retains a 19.84% ownership stake as of March 31, 2026. The agreement includes royalty payments of 7% of sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
For investors, the FDA clearance represents a de-risking event for Lucid-MS and could pave the way for future value creation. The phase 2 trial will be closely watched as it will provide the first human data on this novel mechanism. Success could position Quantum BioPharma as a key player in the MS space, where effective treatments for progressive forms of the disease remain a significant unmet need. To view the full press release, visit https://ibn.fm/lCey9. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
